Advances in biomarkers for immunotherapy in small-cell lung cancer
Small-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The...
Saved in:
| Main Authors: | Hui Li, Peiyan Zhao, Lin Tian, Yuanhua Lu, Xinyue Wang, Wenjun Shao, Ying Cheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490590/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of duration of maintenance immunotherapy on the prognosis of locally advanced non-small cell lung cancer treated with chemoradiotherapy
by: HuiQi Fan, et al.
Published: (2025-07-01) -
TMCO1, as a potential biomarker of prognosis and immunotherapy response, regulates head and neck squamous cell carcinoma proliferation and migration
by: Ting Li, et al.
Published: (2025-05-01) -
ADCYAP1 as a pan-solid cancer biomarker: predictor of immunotherapy efficacy in bladder cancer and prognostic potential across solid tumors
by: Xiaoyu Jing, et al.
Published: (2025-04-01) -
Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies
by: Xiaoyu Yang, et al.
Published: (2025-07-01) -
Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer
by: Liyuan Dai, et al.
Published: (2025-06-01)